A carregar...
Publicação
The biggest healthcare acquisition of 2022: Johnson & Johnson acquires Abiomed Inc
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.75 MB | Adobe PDF |
Autores
Orientador(es)
Resumo(s)
This thesis investigates the rationale, financial elements, and market effects of Johnson &
Johnson's acquisition of Abiomed Inc. in 2022. The acquisition was facilitated in large part by
Abiomed's innovative Impella heart pump technology, which fit in well with Johnson &
Johnson's plan to control the rapidly expanding cardiovascular device market. The $16.6 billion
deal, including the use of contingent value rights to align shareholder interests, is examined in
the report. It also looks at post-acquisition technology integration and regulatory issues,
highlighting the wider implications for future advancements in healthcare and competitive
market positioning.
Descrição
Palavras-chave
Mergers & Acquisition Contingent value right Covid-19 pandemic Corporate strategy Cardiovascular health Healthcare innovation Financial analysis Technological integration